AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03161093
Drug: Fasinumab
RxNorm normalized name: Fasinumab
DrugBank: Fasinumab (DB12157)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution for injection in pre-filled syringe
Trial: NCT03161093
Drug: Fasinumab-matching placebo
DrugBank: Fasinumab (DB12157)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution for injection in pre-filled syringe
Trial: NCT01415895
Drug: Naltrexone and Clonidine Combination
RxNorm normalized name: bupropion and naltrexone
DrugBank: Clonidine (DB00575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: subjects will receive 1 study drug capsule by mouth twice daily for 3 weeks, followed by 1 capsule in the morning for 3 days.
Trial: NCT02002390
Drug: Fingolimod
RxNorm normalized name: Fingolimod
DrugBank: Fingolimod (DB08868)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: A sphingosine-1-phosphate receptor regulator
Trial: NCT01147640
Drug: CXA-101/ tazobactam and metronidazole
DrugBank: Metronidazole (DB00916)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CXA-101/tazobactam (1000/500 mg q8h) plus metronidazole (500 mg q8h) administered via IV infusion
Trial: NCT01147640
Drug: meropenem plus saline placebo
RxNorm normalized name: Meropenem
DrugBank: Meropenem (DB00760)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: meropenem IV infusion (1000 mg q8h) plus a matching saline placebo (q8h) administered via IV infusion
Trial: NCT02163980
Drug: Caudal ropivacaine + normal saline
RxNorm normalized name: NS-2359
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02163980
Drug: Caudal ropivacaine + dexmedetomidine
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04196413
Drug: GD2 CAR T cells
RxNorm normalized name: Anti-BCMA CAR T cell
DrugBank: Idecabtagene vicleucel (DB16665)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autologous T-Cells transduced with retroviral vector (14g2a-CD8.BB.z.iCasp9) expressing GD2-chimeric antigen receptor
Trial: NCT04196413
Drug: Fludarabine
RxNorm normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fludarabine 25 mg/m2 per day IV for days -4, -3, -2
Trial: NCT03666000
Drug: Fludarabine
RxNorm normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specified dose on specified days
Trial: NCT03666000
Drug: IL-2
RxNorm normalized name: IL-2
DrugBank: Human interleukin-2 (DB14865)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specified dose on specified days
Trial: NCT03666000
Drug: Bendamustine
RxNorm normalized name: Bendamustine
DrugBank: Bendamustine (DB06769)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Specified dose on specified days
Trial: NCT00001564
Drug: EF-1 Peptide
RxNorm normalized name: Klor-Con/EF
DrugBank: Potassium bicarbonate (DB11098)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03080974
Drug: Nivolumab
RxNorm normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given post-operatively every two weeks for a total of 4 doses. Dose based on weight.
Trial: NCT01570868
Drug: Ponatinib
RxNorm normalized name: Ponatinib
DrugBank: Ponatinib (DB08901)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Starting dose: 45 mg by mouth once daily.
Trial: NCT04233567
Drug: Infigratinib
RxNorm normalized name: INFIGRATINIB
DrugBank: Infigratinib (DB11886)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT03866408
Drug: Pioglitazone
RxNorm normalized name: Pioglitazone
DrugBank: Pioglitazone (DB01132)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Upper body obese subjects will be block randomized to pioglitazone or placebo at enrollment.
Trial: NCT00001564
Drug: EF-2 Peptide
RxNorm normalized name: Klor-Con/EF
DrugBank: Potassium bicarbonate (DB11098)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00001564
Drug: PXFK Peptide
RxNorm normalized name: peptide-T
DrugBank: Peptide-T (DB19279)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00001564
Drug: E7 Peptide
RxNorm normalized name: HPV E7 Peptide Epitope Vaccine
DrugBank: Verpasep caltespen (DB04959)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00001564
Drug: IL-2
RxNorm normalized name: IL-2
DrugBank: Human interleukin-2 (DB14865)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00001564
Drug: IL-4
RxNorm normalized name: IL-4
DrugBank: Binetrakin (DB12182)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00001564
Drug: GM-CSF
RxNorm normalized name: GM-CSF
DrugBank: Regramostim (DB05386)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00001564
Drug: CD40 Ligand
RxNorm normalized name: CD40 ligand
DrugBank: Recombinant CD40-ligand (DB15015)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00753714
Drug: ZD6474, Vandetanib
DrugBank: Vandetanib (DB05294)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100 mg as a once daily oral dose, from Day 1 until disease progression or unacceptable toxicity or consent withdrawal whichever occurs first
Trial: NCT00753714
Drug: Placebo to Match ZD6474, Vandetanib
DrugBank: Vandetanib (DB05294)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100 mg as a once daily oral dose, from Day 1 UNTIL disease progression or unacceptable toxicity or consent withdrawal whichever occurs first
Trial: NCT00753714
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: administered intravenously at 1200 mg/m2 over 30 minutes on Days 1 and 8 of each 21-day cycle UP to 6 cycles or UNTIL disease progression or unacceptable toxicity or consent withdrawal whichever occurs first
Trial: NCT00744276
Drug: danazol
RxNorm normalized name: Danazol
DrugBank: Danazol (DB01406)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: danazol applied topically once per day for 4 treatment cycles
Trial: NCT04269200
Drug: olaparib
RxNorm normalized name: Olaparib
DrugBank: Olaparib (DB09074)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Olaparib tablets
Trial: NCT04269200
Drug: durvalumab placebo
DrugBank: Durvalumab (DB11714)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Matching placebo for intravenous infusion
Trial: NCT04269200
Drug: olaparib placebo
RxNorm normalized name: Olaparib
DrugBank: Olaparib (DB09074)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Placebo tablets to match olaparib
Trial: NCT04269200
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Standard of care chemotherapy
Trial: NCT04269200
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Standard of care chemotherapy
Trial: NCT03084536
Drug: Bupivacaine
RxNorm normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: -Given after general anesthesia
Trial: NCT03084536
Drug: Gabapentin
RxNorm normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: * As per routine care~* Will not be prescribed for any patient with preexisting kidney disease or ≥ 65 years.
Trial: NCT03084536
Drug: Midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: -As per routine care
Trial: NCT03036904
Drug: Venetoclax
RxNorm normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Venetoclax will be administered orally on days 3-12 in cycle 1, and days 1-10 with all subsequent cycles except dose level -1. If dose level -1 is required, venetoclax will be administered on days 3-7 in cycle 1 and 1-5 with subsequent cycles.
Trial: NCT01792687
Drug: Abiraterone acetate
RxNorm normalized name: ABIRATERONE ACETATE
DrugBank: Abiraterone (DB05812)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 1,000 mg, oral, daily
Trial: NCT01792687
Drug: Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5 mg, oral, daily
Trial: NCT01856478
Drug: afatinib
RxNorm normalized name: Afatinib
DrugBank: Afatinib (DB08916)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: oral intake, once daily
Trial: NCT03587311
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given IV
Trial: NCT01806857
Drug: Nuedexta
RxNorm normalized name: Nuedexta
DrugBank: Dextromethorphan (DB00514)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nuedexta PO (by mouth) for 28 ± 3 days
Trial: NCT04754750
Drug: Paliperidone Palmitate 156 MG/ML Prefilled Syringe [Invega]
RxNorm normalized name: paliperidone palmitate 156 MG/ML Prefilled Syringe [Invega]
DrugBank: Paliperidone (DB01267)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT04754750
Drug: Paliperidone Palmitate 546 MG Intramuscular Suspension, Extended Release [INVEGA TRINZA]
RxNorm normalized name: Paliperidone Palmitate 546 MG Intramuscular Suspension, Extended Release [INVEGA TRINZA]
DrugBank: Paliperidone (DB01267)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT01721057
Drug: Baricitinib
RxNorm normalized name: baricitinib
DrugBank: Baricitinib (DB11817)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered orally
Trial: NCT03331965
Drug: Metoclopramide 5 MG/ML Injectable Solution
RxNorm normalized name: metoclopramide 5 mg/mL injectable solution
DrugBank: Metoclopramide (DB01233)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A one-time dose of promotility agent (metoclopramide 10 mg in 10 mL saline IV) will be administered at the time of GJ placement.
Trial: NCT03331965
Drug: Saline
RxNorm normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A one-time dose of a placebo (10 mL saline IV) will be administered at the time of GJ placement.
Trial: NCT03036904
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rituximab will be administered as an IV infusion at 375 mg/m2 on day 1 of each cycle of DA-EPOCH-R, immediately prior to the start of chemotherapy. Oral pre-medication 650 mg of acetaminophen and 50-100 mg diphenhydramine hydrochloride will be administered 30 to 60 minutes prior to starting each infusion of rituximab. The first rituximab infusion should be started at 50 mg/hr, and increased in 50-mg/hr increments every 30 minutes to a maximum rate of 400 mg/hr. If this rate of escalation is well tolerated the second and subsequent infusions can begin at a rate of 100 mg/hr and increase in 100 mg/hr increments every 30 minutes to a maximum of 400 mg/hr. CAUTION: DO NOT ADMINISTER AS AN INTRAVENOUS PUSH OR BOLUS.
Trial: NCT03036904
Drug: Etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Etoposide will be obtained from commercial supply, and will be given for a total of 6 cycles for all patients. The drug will be given by IV route.
Trial: NCT03036904
Drug: Vincristine Sulfate
RxNorm normalized name: Vincristine Sulfate
DrugBank: Vincristine (DB00541)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vincristine Sulfate will be obtained from commercial supply, and will be given for a total of 6 cycles for all patients. The drug will be given by IV route.
Trial: NCT03036904
Drug: Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisone will be obtained from commercial supply, and will be given for a total of 6 cycles for all patients. Prednisone will be given orally.
Trial: NCT03617510
Drug: Felbinac Trometamol Injection
RxNorm normalized name: felbinac
DrugBank: Felbinac (DB07477)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Felbinac Trometamol Injection will be infused IV in 100 mL normal saline,in a 30-minute period using a programmable pump.Three days after the single dose,the drug was given 7 times,3 times/day,once every 8 hours. It means the drug was given 3 times on D3 and D4,once on D5.
Trial: NCT03087071
Drug: Trametinib
RxNorm normalized name: Trametinib
DrugBank: Trametinib (DB08911)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given PO
Trial: NCT00431678
Drug: Avelox (Moxifloxacin, BAY12-8039)
RxNorm normalized name: moxifloxacin Injection [Avelox]
DrugBank: Moxifloxacin (DB00218)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sequential intravenous/oral (400/400 mg once daily for 7 to 14 days) of Avelox (Moxifloxacin, BAY12-8039)
Trial: NCT00431678
Drug: Levofloxacin + Ceftriaxone
DrugBank: Levofloxacin (DB01137)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous combination therapy of levofloxacin 500 mg twice daily and ceftriaxone (2 g once a day) followed by oral levofloxacin (500 mg twice a day for 7 to 14 days).
Trial: NCT03271528
Drug: Lacosamide
RxNorm normalized name: Lacosamide
DrugBank: Lacosamide (DB06218)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lacosamide titration was done to a target dose of 300mg. Participants took 100 mg of lacosamide once on day 1, 100 mg twice per day from day 2 through day 6 (200 mg daily total), on day 7 the lacosamide dose was increased to 150 mg twice daily (300 mg daily total), and on day 8 the participant took one dose of 150 mg.
Trial: NCT03159117
Drug: PF-06688992
RxNorm normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (PF-06688992) will be administered on Day 1 of each 21-day cycle per the Dose Preparation and Administration Instructions (DAI) located in the Investigational Product Manual (Appendix 4Appendix 3) as an IV infusion over approximately 60 minutes. A cycle is defined as the time from Day 1 dose to the next Day 1 dose. If there are no treatment delays, a cycle will be 21 days. Each patient may receive PF-06688992 until disease progression, unacceptable toxicity, withdrawal of consent, or study termination
Trial: NCT00694707
Drug: Cariprazine
RxNorm normalized name: Cariprazine
DrugBank: Cariprazine (DB06016)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cariprazine was supplied in capsules
Trial: NCT00694707
Drug: Risperidone
RxNorm normalized name: Risperidone
DrugBank: Risperidone (DB00734)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Risperidone was supplied in capsules
Trial: NCT04081324
Drug: Lasmiditan
RxNorm normalized name: lasmiditan
DrugBank: Lasmiditan (DB11732)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered orally
Trial: NCT01785784
Drug: rhGM-CSF Gel
RxNorm normalized name: rGM-CSF
DrugBank: Regramostim (DB05386)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03181815
Drug: Cladribine
RxNorm normalized name: Cladribine
DrugBank: Cladribine (DB00242)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5mg/㎡ d1-5
Trial: NCT03181815
Drug: G-CSF
RxNorm normalized name: G-CSF
DrugBank: Filgrastim (DB00099)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 300ug d0-9
Trial: NCT03181815
Drug: Aclarubicin
RxNorm normalized name: aclarubicin
DrugBank: Aclarubicin (DB11617)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10mg d3-6
Trial: NCT03181815
Drug: Cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 10mg/㎡ q12h SC d3-9
Trial: NCT01537536
Drug: EndoTAG-1
RxNorm normalized name: Endostar
DrugBank: Endostar (DB11727)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EndoTAG-1 (22 mg/m2 liposomal paclitaxel) + Paclitaxel (70 mg/m2) Weekly i.v. infusions of EndoTAG-1 and paclitaxel for 12 weeks followed by subsequent treatment with the standard FEC regimen (Fluorouracil 500 mg/m2, Epirubicin 100 mg/m2, Cyclophosphamide 500 mg/m2) once every 3 weeks for 3 cycles of therapy followed by surgery.
Trial: NCT00067860
Drug: recombinant human growth hormone
RxNorm normalized name: Recombinant human growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01202279
Drug: Guaifenesin
RxNorm normalized name: Guaifenesin
DrugBank: Guaifenesin (DB00874)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1200 mg guaifenesin and 120 mg pseudoephedrine HCl bid for 7 days
Trial: NCT01984164
Drug: Candesartan
RxNorm normalized name: Candesartan
DrugBank: Candesartan (DB13919)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: blinded
Trial: NCT01984164
Drug: Lisinopril
RxNorm normalized name: Lisinopril
DrugBank: Lisinopril (DB00722)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Blinded
Trial: NCT04054089
Drug: Bictegravir 50 MG / Emtricitabine 200 MG / Tenofovir Alafenamide 25 MG [Biktarvy]
RxNorm normalized name: bictegravir 50 MG / emtricitabine 200 MG / tenofovir alafenamide 25 MG [Biktarvy]
DrugBank: Emtricitabine (DB00879)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Biktarvy OD
Trial: NCT04082975
Drug: NVP-1203
RxNorm normalized name: NVP
DrugBank: Nevirapine (DB00238)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral dose for 7 days
Trial: NCT00809809
Drug: Zicam (Ionic zinc)
RxNorm normalized name: Zicam Cough
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 33mmol/l of ionic zinc
Trial: NCT02556736
Drug: RST-001
RxNorm normalized name: RST-001
DrugBank: RST-001 (DB17843)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RST-001 is a gene therapeutic delivered by intravitreal injection
Trial: NCT04054089
Drug: dolutegravir 50 mg / lamivudine 300 mg
RxNorm normalized name: dolutegravir 50 MG / lamiVUDine 300 MG [Dovato]
DrugBank: Lamivudine (DB00709)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: DTG +3TC (Dovato OD)
Trial: NCT00514774
Drug: ursodiol
RxNorm normalized name: Ursodiol
DrugBank: Ursodeoxycholic acid (DB01586)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ursodiol 300 mg twice daily for study days 0 through 28~ursodiol 600mg twice daily on study days 0 through 28
Trial: NCT03594435
Drug: Ibudilast
RxNorm normalized name: ibudilast
DrugBank: Ibudilast (DB05266)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: targets neurotrophin signaling and neuroimmune function
Trial: NCT00832520
Drug: Remeron (mirtazapine)
RxNorm normalized name: mirtazapine Oral Tablet [Remeron]
DrugBank: Mirtazapine (DB00370)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mirtazapine 15 mg orally at bed time. Patients with a creatinine clearance \< 50% or a bilirubin or transaminases \> twice the upper limit of normal will take a 7.5 mg dose.~* Drug Administration: Drug will be administered orally, every day for a period of 8 weeks~* Dose modifications: None
Trial: NCT00789880
Drug: Vitamin D3
RxNorm normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of oral vitamin D3 at 4000IU
Trial: NCT03275792
Drug: Routine home oral rehydration
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Routine oral fluids as is given at home to all children with acute diarrheal disease
Trial: NCT00285818
Drug: Mifepristone
RxNorm normalized name: Mifepristone
DrugBank: Mifepristone (DB00834)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mifepristone is a glucocorticoid receptor antagonist.
Trial: NCT02019277
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dosing regimen to be determined by the investigator, routine clinical practices.
Trial: NCT02019277
Drug: Nab-paclitaxel
RxNorm normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dosing regimen to be determined by the investigator, routine clinical practices.
Trial: NCT02019277
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dosing regimen to be determined by the investigator, routine clinical practices.
Trial: NCT02019277
Drug: Pertuzumab
RxNorm normalized name: Pertuzumab
DrugBank: Pertuzumab (DB06366)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pertuzumab will be administered on Day 1 of the first treatment cycle as a loading dose of 840 mg, followed by 420 mg as an IV infusion every 3 weeks.
Trial: NCT02019277
Drug: Trastuzumab
RxNorm normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Trastuzumab will be administered at a fixed dose of 600 mg SC every 3 weeks.
Trial: NCT04441671
Drug: Disodium Pyrophosphate
RxNorm normalized name: disodium pyrophosphate
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Absorption trial
Trial: NCT01177683
Drug: Bendamustine
RxNorm normalized name: Bendamustine
DrugBank: Bendamustine (DB06769)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Phase I component:~Bendamustine escalating cohorts to determine MTD, IV over 1 hour, Days 1 and 4
Trial: NCT01177683
Drug: Bortezomib
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Phase I and II components:~Bortezomib 1.3 mg/m2 IV bolus, Days 1, 4, 8, and 11
Trial: NCT01177683
Drug: Bendamustine
RxNorm normalized name: Bendamustine
DrugBank: Bendamustine (DB06769)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Phase II component:~Bendamustine at at MTD IV over 1 hour, Days 1 and 4
Trial: NCT01177683
Drug: Filgrastim
RxNorm normalized name: Filgrastim
DrugBank: Filgrastim (DB00099)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Phase II component:~Filgrastim (if defined in MTD) 5 µg/kg/day SC, starting day 6 until neutrophil recovery to ANC \>1000
Trial: NCT02330822
Drug: Hyaluronic Acid
RxNorm normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (DB08818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: This material is going to be injected into the extraction socket in order to promote bone healing.
Trial: NCT01104519
Drug: Niaspan
RxNorm normalized name: Niaspan
DrugBank: Niacin (DB00627)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral doses of 2000 mg of Niaspan once daily for 7 days.